During the past decade, Studienzentrum der Herzklinik Ulm GbR conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 3 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Studienzentrum der Herzklinik Ulm GbR" #1 sponsor was "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company" with 4 trials, followed by "ResMed" with 2 trials sponsored, "Charite University, Berlin, Germany" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "GWT-TUD GmbH" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Studienzentrum der Herzklinik Ulm GbR" #1 collaborator was "CRI-The Clinical Research Institute GmbH" with 1 trials as a collaborator, "ClinStat GmbH" with 1 trials as a collaborator, "Daiichi Sankyo Germany" with 1 trials as a collaborator and "University of Göttingen" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Studienzentrum der Herzklinik Ulm GbR" are "Hypercholesterolemia" (3 trials), "Atrial Fibrillation" (2 trials), "Heart Failure" (2 trials), "Mixed Dyslipidemia" (2 trials) and "Atherosclerotic Cardiovascular Disease" (1 trials). Many other conditions were trialed in "Studienzentrum der Herzklinik Ulm GbR" in a lesser frequency.

Most popular intervention types in "Studienzentrum der Herzklinik Ulm GbR" are "Drug" (5 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Edoxaban" (2 trials), "Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab" (1 trials), "Bempedoic acid and/or its fixed-dose combination with ezetimibe" (1 trials), "Clopidogrel" (1 trials) and "Europe: AutoSet CS (USA: VPAP Adapt SV)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Studienzentrum der Herzklinik Ulm GbR" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Studienzentrum der Herzklinik Ulm GbR". 1 are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Studienzentrum der Herzklinik Ulm GbR, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Studienzentrum der Herzklinik Ulm GbR, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".